Literature DB >> 2439706

Antibodies against the two serotypes of vesicular stomatitis virus measured by enzyme-linked immunosorbent assay: immunodominance of serotype-specific determinants and induction of asymmetrically cross-reactive antibodies.

S Charan, H Hengartner, R M Zinkernagel.   

Abstract

The serological relationship between the two vesicular stomatitis virus (VSV) strains Indiana (VSV-Ind) and New Jersey (VSV-NJ) were analyzed by using an enzyme-linked immunosorbent assay (ELISA). Immunoglobulin G responses, defined by their resistance to treatment with 2-mercaptoethanol, were assessed by ELISA by using sucrose gradient-purified VSV or purified VSV glycoproteins (G) as antigens. When low doses (10(6) PFU) of live VSV or 10(8) PFU of UV-inactivated virus were given intraperitoneally (i.p.), only non-cross-reactive antibody responses were observed in a primary immune response. However, when 10(6) PFU of live VSV were injected intravenously (i.v.), cross-reactive antibodies were generated; anti-VSV-NJ antibodies cross-reacted more against VSV-Ind than did anti-VSV-Ind antibodies against VSV-NJ. When 10(8) PFU of live VSV or UV-inactivated VSV mixed with complete Freund adjuvant was given i.p., high levels of cross-reactive antibodies detectable by ELISA were induced in primary and secondary responses. When purified G protein was used instead of purified whole virus in the ELISA, the cross-reactivity was found to be asymmetrical after immunization with live VSV given i.v. but not after i.p. inoculation; anti-VSV-NJ sera bound almost equally well to VSV-Ind G protein, whereas anti-VSV-Ind sera bound virtually exclusively to the G protein of the homologous serotype. The data suggest that immunization with VSV given i.p. results in a more specific, i.e., less cross-reactive, response than that either after i.v. infection or after the virus antigen is made available in great amounts or if it persists for prolonged periods when given i.p. together with complete Freund adjuvant. The unique determinants were immunodominant because they induced antibodies preferentially, whereas partially shared determinants induced antibody responses asymmetrically, more slowly, and with lower titers. Interestingly, the asymmetric cross-reactivity of anti-VSV antibodies, as measured by ELISA, against purified VSV G was opposite that observed for cytotoxic T cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2439706      PMCID: PMC255681     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  13 in total

1.  Cell-mediated immunity to vesicular stomatitis virus infections in mice.

Authors:  R M Zinkernagel; B Adler; J J Holland
Journal:  Exp Cell Biol       Date:  1978

2.  The role of vesicular stomatitis virus major glycoprotein in determining the specificity of virus-specific and H-2-restricted cytolytic T cells.

Authors:  K K Sethi; H Brandis
Journal:  Eur J Immunol       Date:  1980-04       Impact factor: 5.532

3.  Serological characterization of the three major proteins of vesicular stomatitis virus.

Authors:  B Dietzschold; L G Schneider; J H Cox
Journal:  J Virol       Date:  1974-07       Impact factor: 5.103

4.  The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody.

Authors:  J M Kelley; S U Emerson; R R Wagner
Journal:  J Virol       Date:  1972-12       Impact factor: 5.103

5.  Cross-reactive cytotoxic T cells to serologically distinct vesicular stomatitis virus.

Authors:  K L Rosenthal; R M Zinkernagel
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

6.  The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. II. Monoclonal antibodies of nonneutralizing and cross-reactive epitopes of Indiana and New Jersey serotypes.

Authors:  L Lefrancois; D S Lyles
Journal:  Virology       Date:  1982-08       Impact factor: 3.616

7.  Monoclonal antibodies to the glycoprotein of vesicular stomatitis virus: comparative neutralizing activity.

Authors:  W A Volk; R M Synder; D C Benjamin; R R Wagner
Journal:  J Virol       Date:  1982-04       Impact factor: 5.103

8.  Antibody mediated suppression of secondary IgM response in nude mice against vesicular stomatitis virus.

Authors:  S Charan; R M Zinkernagel
Journal:  J Immunol       Date:  1986-04-15       Impact factor: 5.422

9.  Lipid composition of purified vesicular stomatitis viruses.

Authors:  J J McSharry; R R Wagner
Journal:  J Virol       Date:  1971-01       Impact factor: 5.103

10.  Activation of mouse lymphocytes by vesicular stomatitis virus.

Authors:  G W Goodman-Snitkoff; J J McSharry
Journal:  J Virol       Date:  1980-09       Impact factor: 5.103

View more
  5 in total

1.  Fewer protective cytotoxic T-cell epitopes than T-helper-cell epitopes on vesicular stomatitis virus.

Authors:  T M Kündig; I Castelmur; M F Bachmann; D Abraham; D Binder; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

2.  Cytokine-modified VSV is attenuated for neural pathology, but is both highly immunogenic and oncolytic.

Authors:  James Miller; Sarah M Bidula; Troels M Jensen; Carol Shoshkes Reiss
Journal:  Int J Interferon Cytokine Mediat Res       Date:  2009-12-01

3.  Development of a competitive enzyme-linked immunosorbent assay for detection of bovine, ovine, porcine, and equine antibodies to vesicular stomatitis virus.

Authors:  A Afshar; N H Shakarchi; G C Dulac
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

4.  Secondary rearrangements and hypermutation generate sufficient B cell diversity to mount protective antiviral immunoglobulin responses.

Authors:  C López-Macías; U Kalinke; M Cascalho; M Wabl; H Hengartner; R M Zinkernagel; A Lamarre
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

5.  Chronic Viral Infection Promotes Efficient Germinal Center B Cell Responses.

Authors:  Bénédict Fallet; Yi Hao; Marianna Florova; Karen Cornille; Alba Verge de Los Aires; Giulia Girelli Zubani; Yusuf I Ertuna; Victor Greiff; Ulrike Menzel; Karim Hammad; Doron Merkler; Sai T Reddy; Jean-Claude Weill; Claude-Agnès Reynaud; Daniel D Pinschewer
Journal:  Cell Rep       Date:  2020-01-28       Impact factor: 9.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.